Travere Therapeutics (TVTX) Loans and Notes Receivables (2016 - 2017)
Historic Loans and Notes Receivables for Travere Therapeutics (TVTX) over the last 3 years, with Q1 2017 value amounting to $47.2 million.
- Travere Therapeutics' Loans and Notes Receivables changed 0.0% to $47.2 million in Q1 2017 from the same period last year, while for Mar 2017 it was $47.2 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $46.8 million for FY2016, which is 0.0% changed from last year.
- According to the latest figures from Q1 2017, Travere Therapeutics' Loans and Notes Receivables is $47.2 million, which was down 0.0% from $46.8 million recorded in Q4 2016.
- Travere Therapeutics' 5-year Loans and Notes Receivables high stood at $47.5 million for Q2 2016, and its period low was $46.5 million during Q3 2015.
- Moreover, its 3-year median value for Loans and Notes Receivables was $46.8 million (2015), whereas its average is $46.9 million.
- Data for Travere Therapeutics' Loans and Notes Receivables shows a peak YoY increase of 0.0% (in 2016) and a maximum YoY decrease of 0.0% (in 2016) over the last 5 years.
- Quarter analysis of 3 years shows Travere Therapeutics' Loans and Notes Receivables stood at $46.8 million in 2015, then changed by 0.0% to $46.8 million in 2016, then increased by 0.69% to $47.2 million in 2017.
- Its Loans and Notes Receivables was $47.2 million in Q1 2017, compared to $46.8 million in Q4 2016 and $46.5 million in Q3 2016.